2
|
Begasse De Dhaem O, Aldana SI, Kanner AM, Sperling M, French J, Nadkarni SS, Hope OA, O'Brien T, Morrison C, Winawer M, Minen MT. Association Between Migraine Comorbidity and Psychiatric Symptoms Among People With Newly Diagnosed Focal Epilepsy. J Neuropsychiatry Clin Neurosci 2022; 34:182-187. [PMID: 34961330 DOI: 10.1176/appi.neuropsych.21050124] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Little is known about psychiatric symptoms among patients with migraine and newly diagnosed focal epilepsy. The investigators compared symptoms of depression, anxiety, and suicidality among people with newly diagnosed focal epilepsy with migraine versus without migraine. METHODS The Human Epilepsy Project is a prospective multicenter study of patients with newly diagnosed focal epilepsy. Depression (measured with the Center for Epidemiologic Studies Depression Scale), anxiety (measured with the 7-item Generalized Anxiety Disorder scale), and suicidality scores (measured with the Columbia-Suicide Severity Rating Scale [C-SSRS]) were compared between participants with versus without migraine. Data analysis was performed with the Kolmogorov-Smirnov test for normality assessment, the Mann-Whitney U test, chi-square test, and linear regression. RESULTS Of 349 patients with new-onset focal epilepsy, 74 (21.2%) had migraine. There were no differences between the patients without migraine versus those with migraine in terms of age, race, and level of education. There were more women in the group with migraine than in the group without migraine (75.7% vs. 55.6%, p=0.0018). The patients with epilepsy and comorbid migraine had more depressive symptoms than the patients with epilepsy without migraine (35.2% vs. 22.7%, p=0.031). Patients with epilepsy with comorbid migraine had more anxiety symptoms than patients with epilepsy without migraine, but this relation was mediated by age in logistic regression, with younger age being associated with anxiety. Comorbid migraine was not associated with C-SSRS ideation or behavior. CONCLUSIONS Among a sample of patients with newly diagnosed focal epilepsy, 21.2% had migraine. Migraine comorbidity was associated with higher incidence of depressive symptoms. Future studies should be performed to better assess these relationships and possible treatment implications.
Collapse
Affiliation(s)
- Olivia Begasse De Dhaem
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Sandra India Aldana
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Andres Miguel Kanner
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Michael Sperling
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Jacqueline French
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Siddhartha S Nadkarni
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Omotola A Hope
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Terry O'Brien
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Chris Morrison
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Melodie Winawer
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| | - Mia T Minen
- New York-Presbyterian Hospital/Columbia University, New York (Begasse De Dhaem); Office of Science and Research, New York University Langone Health, New York (Aldana); Division of Epilepsy, Miller School of Medicine, University of Miami, Miami (Kanner); Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia (Sperling); New York University School of Medicine, Comprehensive Epilepsy Center, New York University Langone Health, New York (French, Nadkarni, Morrison); Department of Neurology, McGovern Medical School, University of Texas Health Science Center-Houston (Hope); The Central Clinical School, Monash University, Melbourne, Victoria, Australia (O'Brien); Gertrude H. Sergievsky Center, Columbia University, New York (Winawer); and Departments of Neurology and Population Health, New York University Langone Health, New York (Minen)
| |
Collapse
|
5
|
Fisher K, Griffith LE, Gruneir A, Kanters D, Markle-Reid M, Ploeg J. Functional limitations in people with multimorbidity and the association with mental health conditions: Baseline data from the Canadian Longitudinal Study on Aging (CLSA). PLoS One 2021; 16:e0255907. [PMID: 34379653 PMCID: PMC8357170 DOI: 10.1371/journal.pone.0255907] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Accepted: 07/26/2021] [Indexed: 12/26/2022] Open
Abstract
INTRODUCTION Increasing multimorbidity is often associated with declining physical functioning, with some studies showing a disproportionate impact on functioning when mental health conditions are present. More research is needed because most multimorbidity studies exclude mental health conditions. OBJECTIVES This study aims to improve our understanding of the association between functional limitation and multimorbidity, including a comparison of those with multimorbidity that includes versus excludes mental health conditions. METHODS This is a population-based, cross-sectional analysis of data from The Canadian Longitudinal Study on Aging. Functional limitation was defined as the presence of any of 14 activities of daily living (ADLs) or instrumental activities of daily living (IADLs). Multimorbidity, measured by the number of chronic conditions, included mood and anxiety disorders. Logistic regression explored the association between multimorbidity (with and without mental health conditions) and functional limitation. Factor analysis identified common condition clusters to help understand clinical complexity in those with mood/anxiety disorders and the potential influences on functional limitation. RESULTS There were 51,338 participants, with a similar proportion of men and women (49% versus 51%) and 42% age 65 years or older. Fifteen percent (15%) had no chronic conditions and 17% had 5+. Ten percent (10%) reported at least one ADL or IADL limitation. Odds ratios (ORs) for functional limitation increased with multimorbidity and were generally higher for those with versus without mental health conditions (e.g., ORs from 1 to 5+ chronic conditions increased 1.9 to 15.8 for those with mood/anxiety disorders versus 1.8 to 10.2 for those without). Factor analysis showed that mood/anxiety conditions clustered with somatic conditions (e.g., migraines, bowel/gastrointestinal disorders). CONCLUSION This study found higher odds of functional limitation for those with multimorbidity that included versus excluded mental health conditions, at all levels of multimorbidity. It highlights the need for concurrent management of mental and physical comorbidities to prevent functional limitations and future decline. This approach is aligned with the NICE clinical assessment and management guidelines for people with multimorbidity.
Collapse
Affiliation(s)
- Kathryn Fisher
- School of Nursing, McMaster University, Hamilton, Ontario, Canada
- * E-mail:
| | - Lauren E. Griffith
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Andrea Gruneir
- Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
- ICES, Toronto, Ontario, Canada
| | - David Kanters
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Maureen Markle-Reid
- School of Nursing, McMaster University, Hamilton, Ontario, Canada
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Jenny Ploeg
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
6
|
Steriade C, Titulaer MJ, Vezzani A, Sander JW, Thijs RD. The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain 2021; 144:372-390. [PMID: 33221878 DOI: 10.1093/brain/awaa362] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 08/03/2020] [Accepted: 08/13/2020] [Indexed: 12/12/2022] Open
Abstract
Systemic autoimmune disorders occur more frequently in patients with epilepsy than in the general population, suggesting shared disease mechanisms. The risk of epilepsy is elevated across the spectrum of systemic autoimmune disorders but is highest in systemic lupus erythematosus and type 1 diabetes mellitus. Vascular and metabolic factors are the most important mediators between systemic autoimmune disorders and epilepsy. Systemic immune dysfunction can also affect neuronal excitability, not only through innate immune activation and blood-brain barrier dysfunction in most epilepsies but also adaptive immunity in autoimmune encephalitis. The presence of systemic autoimmune disorders in subjects with acute seizures warrants evaluation for infectious, vascular, toxic and metabolic causes of acute symptomatic seizures, but clinical signs of autoimmune encephalitis should not be missed. Immunosuppressive medications may have antiseizure properties and trigger certain drug interactions with antiseizure treatments. A better understanding of mechanisms underlying the co-existence of epilepsy and systemic autoimmune disorders is needed to guide new antiseizure and anti-epileptogenic treatments. This review aims to summarize the epidemiological evidence for systemic autoimmune disorders as comorbidities of epilepsy, explore potential immune and non-immune mechanisms, and provide practical implications on diagnostic and therapeutic approach to epilepsy in those with comorbid systemic autoimmune disorders.
Collapse
Affiliation(s)
- Claude Steriade
- Department of Neurology, New York University School of Medicine, New York, NY, USA
| | - Maarten J Titulaer
- Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Annamaria Vezzani
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Josemir W Sander
- NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.,Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, Bucks, UK.,Stichting Epilepsie Instellingen Nederland - (SEIN), Heemstede, The Netherlands
| | - Roland D Thijs
- NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.,Stichting Epilepsie Instellingen Nederland - (SEIN), Heemstede, The Netherlands.,Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands
| |
Collapse
|